Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Phase I Clinical Trial
100%
Metastatic Non-small Cell Lung Cancer
100%
Engineered T Cells
100%
New York Esophageal Squamous Cell carcinoma-1
100%
Adoptive Cell Therapy
71%
T Cell Receptor-engineered T Cells
71%
Clinical Trials
28%
Non-small Cell Lung Cancer (NSCLC)
28%
Clinical Response
28%
Lung Adenocarcinoma
28%
Cancer-testis Antigen
28%
Human Leukocyte Antigen
28%
Partial Response
14%
White Blood Cell Count
14%
Anemia
14%
Fever
14%
Serious Adverse Events
14%
Adverse Events
14%
Clinical Assessment
14%
Patients with Advanced Cancer
14%
Lung Cancer Patients
14%
T Cell Targeting
14%
Karnofsky Performance Status
14%
Drug Sensitivity
14%
Older Female Patient
14%
Laboratory Assessment
14%
Medicine and Dentistry
Clinical Trial
100%
Non Small Cell Lung Cancer
100%
T Cell
100%
T Cell Receptor
100%
Esophageal Squamous Cell Carcinoma
100%
T Lymphocyte Receptor
71%
Cell Therapy
71%
Adverse Event
28%
Lung Adenocarcinoma
28%
Cancer Testis Antigen
28%
Human Leukocyte Antigen
28%
Lung Cancer
14%
Leukocyte
14%
Infusion
14%
Cell Count
14%
Anemia
14%
Clinical Assessment
14%
Advanced Cancer
14%
Karnofsky Performance Status
14%
Drug Sensitivity
14%
Laboratory Assessment
14%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Non Small Cell Lung Cancer
100%
Esophageal Squamous Cell Carcinoma
100%
T Lymphocyte Receptor
71%
Adverse Event
28%
Lung Adenocarcinoma
28%
Cancer Testis Antigen
28%
Leukocyte Antigen
28%
Lung Cancer
14%
Anemia
14%
Advanced Cancer
14%
Immunology and Microbiology
T Cell
100%
T Cell Receptor
100%
Squamous Cell
100%
Cancer Testis Antigen
28%
Human Leukocyte Antigen
28%
Leukocyte Count
14%
Drug Sensitivity
14%